EGF induces epithelial-mesenchymal transition through phospho-Smad2/3-Snail signaling pathway in breast cancer cells

Jinkyoung Kim, Jienan Kong, Hyeyoon Chang, Hayeon Kim, Aeree Kim

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Epithelial-mesenchymal transition (EMT) can contribute to tumor invasion, metastasis, and resistance to chemotherapy or hormone therapy. EMT may be induced by a variety of growth factors, such as epidermal growth factor (EGF). Most studies regarding EMT have focused on TGF-β-Smads signaling. The mechanism of EGF-induced EMT via activation of the Smad2/3 in breast cancer cells, MCF-7 and MDA-MB-231, remains unclear. The expression levels of Snail, vimentin, and fibronectin were increased by EGF treatment in a time-dependent manner, while the expression level of E-cadherin was decreased. EGF-induced nuclear co-localization of phospho-Smad2/3 and Snail and cancer cell migration were inhibited by pretreatment with an ERK1/2 inhibitor, PD98059 and a phospho-Smad2 inhibitor, SB203580. Knockdown of Smad2/3 expression suppressed EGF-induced expressions of Snail, vimentin, fibronectin, and cancer cell invasion, suggesting an acquisition of the mesenchymal and migratory phenotype in less aggressive MCF-7 cells. Moreover, MDA-MB-231 cells were shown that EGF-induced EMT, and cell invasion through ERK1/2-phospho-Smad2/3-Snail signaling pathway. We have discovered that EGF-stimulated activation of Smad2/3 upregulated several key EMT markers, inhibited E-cadherin expression, promoted EMT, enhanced migration and invasion in MCF-7 and MDA-MB-231 breast cancer cells. Identification of this molecular mechanism may provide new molecular targets for the development of therapies for metastatic breast cancer.

Original languageEnglish
Pages (from-to)85021-85032
Number of pages12
JournalOncotarget
Volume7
Issue number51
DOIs
Publication statusPublished - 2016

Fingerprint

Epithelial-Mesenchymal Transition
Snails
Epidermal Growth Factor
Breast Neoplasms
MCF-7 Cells
Vimentin
Cadherins
Fibronectins
Neoplasms
Cell Movement
Intercellular Signaling Peptides and Proteins
Therapeutics
Hormones
Neoplasm Metastasis
Phenotype
Drug Therapy

Keywords

  • Breast cancer
  • EMT
  • Epidermal growth factor (EGF)
  • Smad2/3
  • Small interfering RNA (siRNA)

ASJC Scopus subject areas

  • Oncology

Cite this

EGF induces epithelial-mesenchymal transition through phospho-Smad2/3-Snail signaling pathway in breast cancer cells. / Kim, Jinkyoung; Kong, Jienan; Chang, Hyeyoon; Kim, Hayeon; Kim, Aeree.

In: Oncotarget, Vol. 7, No. 51, 2016, p. 85021-85032.

Research output: Contribution to journalArticle

Kim, Jinkyoung ; Kong, Jienan ; Chang, Hyeyoon ; Kim, Hayeon ; Kim, Aeree. / EGF induces epithelial-mesenchymal transition through phospho-Smad2/3-Snail signaling pathway in breast cancer cells. In: Oncotarget. 2016 ; Vol. 7, No. 51. pp. 85021-85032.
@article{57b5082adc7f438e9530bcdc10e231cb,
title = "EGF induces epithelial-mesenchymal transition through phospho-Smad2/3-Snail signaling pathway in breast cancer cells",
abstract = "Epithelial-mesenchymal transition (EMT) can contribute to tumor invasion, metastasis, and resistance to chemotherapy or hormone therapy. EMT may be induced by a variety of growth factors, such as epidermal growth factor (EGF). Most studies regarding EMT have focused on TGF-β-Smads signaling. The mechanism of EGF-induced EMT via activation of the Smad2/3 in breast cancer cells, MCF-7 and MDA-MB-231, remains unclear. The expression levels of Snail, vimentin, and fibronectin were increased by EGF treatment in a time-dependent manner, while the expression level of E-cadherin was decreased. EGF-induced nuclear co-localization of phospho-Smad2/3 and Snail and cancer cell migration were inhibited by pretreatment with an ERK1/2 inhibitor, PD98059 and a phospho-Smad2 inhibitor, SB203580. Knockdown of Smad2/3 expression suppressed EGF-induced expressions of Snail, vimentin, fibronectin, and cancer cell invasion, suggesting an acquisition of the mesenchymal and migratory phenotype in less aggressive MCF-7 cells. Moreover, MDA-MB-231 cells were shown that EGF-induced EMT, and cell invasion through ERK1/2-phospho-Smad2/3-Snail signaling pathway. We have discovered that EGF-stimulated activation of Smad2/3 upregulated several key EMT markers, inhibited E-cadherin expression, promoted EMT, enhanced migration and invasion in MCF-7 and MDA-MB-231 breast cancer cells. Identification of this molecular mechanism may provide new molecular targets for the development of therapies for metastatic breast cancer.",
keywords = "Breast cancer, EMT, Epidermal growth factor (EGF), Smad2/3, Small interfering RNA (siRNA)",
author = "Jinkyoung Kim and Jienan Kong and Hyeyoon Chang and Hayeon Kim and Aeree Kim",
year = "2016",
doi = "10.18632/oncotarget.13116",
language = "English",
volume = "7",
pages = "85021--85032",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "51",

}

TY - JOUR

T1 - EGF induces epithelial-mesenchymal transition through phospho-Smad2/3-Snail signaling pathway in breast cancer cells

AU - Kim, Jinkyoung

AU - Kong, Jienan

AU - Chang, Hyeyoon

AU - Kim, Hayeon

AU - Kim, Aeree

PY - 2016

Y1 - 2016

N2 - Epithelial-mesenchymal transition (EMT) can contribute to tumor invasion, metastasis, and resistance to chemotherapy or hormone therapy. EMT may be induced by a variety of growth factors, such as epidermal growth factor (EGF). Most studies regarding EMT have focused on TGF-β-Smads signaling. The mechanism of EGF-induced EMT via activation of the Smad2/3 in breast cancer cells, MCF-7 and MDA-MB-231, remains unclear. The expression levels of Snail, vimentin, and fibronectin were increased by EGF treatment in a time-dependent manner, while the expression level of E-cadherin was decreased. EGF-induced nuclear co-localization of phospho-Smad2/3 and Snail and cancer cell migration were inhibited by pretreatment with an ERK1/2 inhibitor, PD98059 and a phospho-Smad2 inhibitor, SB203580. Knockdown of Smad2/3 expression suppressed EGF-induced expressions of Snail, vimentin, fibronectin, and cancer cell invasion, suggesting an acquisition of the mesenchymal and migratory phenotype in less aggressive MCF-7 cells. Moreover, MDA-MB-231 cells were shown that EGF-induced EMT, and cell invasion through ERK1/2-phospho-Smad2/3-Snail signaling pathway. We have discovered that EGF-stimulated activation of Smad2/3 upregulated several key EMT markers, inhibited E-cadherin expression, promoted EMT, enhanced migration and invasion in MCF-7 and MDA-MB-231 breast cancer cells. Identification of this molecular mechanism may provide new molecular targets for the development of therapies for metastatic breast cancer.

AB - Epithelial-mesenchymal transition (EMT) can contribute to tumor invasion, metastasis, and resistance to chemotherapy or hormone therapy. EMT may be induced by a variety of growth factors, such as epidermal growth factor (EGF). Most studies regarding EMT have focused on TGF-β-Smads signaling. The mechanism of EGF-induced EMT via activation of the Smad2/3 in breast cancer cells, MCF-7 and MDA-MB-231, remains unclear. The expression levels of Snail, vimentin, and fibronectin were increased by EGF treatment in a time-dependent manner, while the expression level of E-cadherin was decreased. EGF-induced nuclear co-localization of phospho-Smad2/3 and Snail and cancer cell migration were inhibited by pretreatment with an ERK1/2 inhibitor, PD98059 and a phospho-Smad2 inhibitor, SB203580. Knockdown of Smad2/3 expression suppressed EGF-induced expressions of Snail, vimentin, fibronectin, and cancer cell invasion, suggesting an acquisition of the mesenchymal and migratory phenotype in less aggressive MCF-7 cells. Moreover, MDA-MB-231 cells were shown that EGF-induced EMT, and cell invasion through ERK1/2-phospho-Smad2/3-Snail signaling pathway. We have discovered that EGF-stimulated activation of Smad2/3 upregulated several key EMT markers, inhibited E-cadherin expression, promoted EMT, enhanced migration and invasion in MCF-7 and MDA-MB-231 breast cancer cells. Identification of this molecular mechanism may provide new molecular targets for the development of therapies for metastatic breast cancer.

KW - Breast cancer

KW - EMT

KW - Epidermal growth factor (EGF)

KW - Smad2/3

KW - Small interfering RNA (siRNA)

UR - http://www.scopus.com/inward/record.url?scp=85007504890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007504890&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.13116

DO - 10.18632/oncotarget.13116

M3 - Article

C2 - 27829223

AN - SCOPUS:85007504890

VL - 7

SP - 85021

EP - 85032

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 51

ER -